Absolem allies with AREV to grow into top mushroom extraction soln
By Nikita Chaurasia  Date: 2019-11-29

Absolem allies with AREV to grow into top mushroom extraction soln

Absolem Extractions, a subsidiary of Absolem Health, recently signed a definitive deal with AREV. The deal is expected to position Absolem as the leading solution for functional extraction of mushrooms. For the uninitiated, AREV delivers and creates functional ingredients and compounds, while Absolem offers extractions for the functional food market, particularly in mushrooms.

Speaking on the development, Ken Kuiper, CEO, Absolem, said that the company is thrilled about the expanding global interest in functional mushrooms. The company feels that it has the potential to become the best commercial extraction unit in the market, and AREV’s extensive knowledge in extractions could majorly help Absolem reach its peak.

Michael Withrow, CEO, AREV, meanwhile said that Absolem’s team has identified huge growth in natural medicines. Their company is pleased to be a part of this innovation and hopes that this partnership would lead to the production of another line of formulations and branded ingredients, contributing towards strengthening its revenue stream.

Reportedly, Absolem Health has also finalized the purchase of One Up Pure Energy, a beverage and food line of functional mushroom powders, snacks, teas, and mushroom-based meat alternative protein items.

Prior to this, the Yield Growth Corp. had made its entry into the edible mushroom market when its subsidiary, Flourish Mushroom Labs Inc. inked a deal to acquire 9 recipes that include edible mushrooms as an important ingredient.

According to reliable sources, the recipes come from various creators which include, a holistic health coach and food chemist, a chef and a chemical engineer. Moreover, the deal was expected to be finalized under 30 days.

Yield Growth has also agreed to purchase 30% of Absolem Health Corp. (owner of One Up Pure Energy). For the uninitiated, Absolem Health holds Health Canada approval for edible mushroom snacks.

As for Absolem Extractions and AREV deal, details regarding to the terms of the agreement will be announced when the transaction is finalized. However, it would be subject to the approval of the CSE.

Source Credit: https://www.nutraceuticalbusinessreview.com/news/article_page/Absolem_enters_mushroom_extraction_joint_venture/160416

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Fragomen acquires SimpleCitizen to reinforce its immigration services
Fragomen acquires SimpleCitizen to reinforce its immigration services
By Nikita Chaurasia

In a recent turn of events, Fragomen, Del Rey, Bernsen & Loewy, LLP, a leading corporate immigration law company has reportedly joined hands with SimpleCitizen Inc. to form Fragomen Technologies Inc., a new subsidiary which will provide a combina...

Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
By Nikita Chaurasia

Solar project development and asset management major, Nautilus Solar Energy LLC, has reportedly announced its acquisition of two solar portfolios in Rhode Island and Oregon amounting to a total of nearly 17 MW from leading solar energy developer, Pin...

Locate Bio obtains multiple late stage orthobiologics assets from RCSI
Locate Bio obtains multiple late stage orthobiologics assets from RCSI
By Nikita Chaurasia

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences. Sources state that the technologies created by the RCSI Tissue E...

Roche acquires Inflazome to gain control over inflammatory treatments
Roche acquires Inflazome to gain control over inflammatory treatments
By Nikita Chaurasia

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million). As per the agreement, Roche will acquire complete rights ...

Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
By Nikita Chaurasia

Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Soci...